Fig. 1

CD2AP expression is increased in the brain of AD patients and 5xFAD mice. A Comparison of CD2AP protein levels in the brain of AD patients (n = 173), asymptomatic AD (Asym_AD, n = 177) patients, and control subjects (n = 117) from a proteomic study [53]. 1-way ANOVA with two-sided Holm correction. B CD2AP protein levels in hippocampal tissues of WT (n = 6) and 5xFAD (n = 7) mice at 7 months of age were analyzed by western blot and quantified for comparison. Unpaired Student’s t test. C CD2AP protein levels in hippocampal tissues of WT and 5xFAD mice at 1.5 months of age were analyzed by western blot and quantified for comparison. n = 6 per group. Unpaired Student’s t test. D CD2AP protein levels in cultured primary neurons, microglia, and astrocytes were analyzed by western blot and quantified for comparison. NeuN, GFAP, and Iba1 were markers for neurons, astrocytes, and microglia, respectively. n = 3. 1-way ANOVA followed by Dunnett's post hoc test. E CD2AP protein levels in hippocampal tissues of 5-month-old WT and 5xFAD mice treated with or without PLX3397 were analyzed by western blot and quantified for comparison. CSF1R was studied to indicate the effect of PLX3397 treatment. n = 3. 2-way ANOVA followed by Sidak’s post hoc test. Data are presented as mean ± SEM. *P < 0.05; ns, not significant